ClinicalTrials.gg
CompletedNCT06104189Updated Oct 27, 2023

Prospective Ultrafast MRI Radiomics for Breast Cancer

An observational study in Breast Cancer, sponsored by Korea University Ansan Hospital. Completed at 1 site in Korea, Republic of. Open to female participants aged 27 Years to 86 Years. Per ClinicalTrials.gov, last updated 2023-10-27.

Sponsored by Korea University Ansan Hospital · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
225
Ages
27 Years to 86 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 618 studies in Breast Neoplasms with a site in Korea, Republic of — 132 open to participants now, 230 under way, 75 of them phase 3. Breast Neoplasms · Korea, Republic of.

Enrollment
68th of 109
225 · median 444
Started
2021
with 42 others
Observational
110 of 618
30 open now
Registered
505th of 618
by date

Among the 618 studies in Breast Neoplasms with a site in Korea, Republic of, this one is the 68th largest by enrollment of the 109 observational ones that give a count, is one of 43 that started in 2021, is one of 110 observational ones, and was the 505th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

132 of the 618 studies in Breast Neoplasms with a site in Korea, Republic of are open now. Recruiting first, the newest first:

127 more — sign in →

All 132 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 27 Years to 86 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 618 studies in Breast Neoplasms with a site in Korea, Republic of, or all of them as a file.
02

Study summary

The goal of this prospective study is to investigate the performance of ultrafast MRI radiomics in classifying histological factors and subtypes of breast cancer compared with standard MRI among radiologists with varying experience. The written informed consent was obtained from all participant. We extracted 1618 radiomic features from ultrafast and standard contrast-enhanced MRI before treatment. Classification of hormonal receptors, human epidermal growth factor receptor 2, and Ki67 status and subtypes was evaluated using the area under the receiver-operating characteristic curve (AUC) with the DeLong test.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
27 Years to 86 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population should fulfill the following criteria as follows:(a) histologically confirmed invasive breast cancer, (b) participant consent, and (c) MRI performed before treatment.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed with invasive breast cancer

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with other cancer
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
225 participants (actual)
Target follow-up
3 Years
Patient registry
Yes

Interventions

  • Diagnostic testMRI

    MRI based classification of breast cancer histological factors and subtypes

06

What researchers measure

Primary outcomes

  1. The signal intensity of MRI according to histological factors and subtypes of breast cancer

    Quantitative image values obtained from ultrafast MRI show similar performance in classifying histological factors and subtypes compared with standard MRI.

    Time frame: Baseline, pre-surgery

07

Study locations

1 site
  • Bo Kyoung Seo
    Ansan, 15355, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2021 to primary completion in Nov 2022, 13 months.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's 13 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Oct 27, 2023
StartActual
Oct 1, 2021
Primary completionActual
Nov 30, 2022
CompletionActual
Aug 31, 2023
Last update
Oct 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06104189
Lead sponsor
Korea University Ansan Hospital
Responsible party
Bo Kyoung Seo (Professor, Korea University Ansan Hospital) — Principal investigator
First posted
Oct 27, 2023
Start date
Oct 1, 2021
Primary completion
Nov 30, 2022
Completion
Aug 31, 2023
Last update
Oct 27, 2023

Study contacts

Bo Kyoung Seo, MD, PhD
principal investigator · Korea University Ansan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion